AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan, RJ Valentine… - … syndrome and obesity …, 2014 - Taylor & Francis
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan, RJ Valentine, NB Ruderman… - … Syndrome and Obesity, 2014 - dovepress.com
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan, RJ Valentine, NB Ruderman… - … Syndrome and Obesity …, 2014 - go.gale.com
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance,[beta]-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan, RJ Valentine… - … targets and therapy, 2014 - pubmed.ncbi.nlm.nih.gov
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
[PDF][PDF] AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan - 2014 - pdfs.semanticscholar.org
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
[引用][C] AMPK activation: a therapeutic target for type 2 diabetes?
A Saha, K Coughlan, R Valentine… - … , Metabolic Syndrome and …, 2014 - cir.nii.ac.jp
AMPK activation: a therapeutic target for type 2 diabetes? | CiNii Research CiNii 国立情報学
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データをさがす 大学 …
[PDF][PDF] AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan - 2014 - moodle2.units.it
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
[HTML][HTML] AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan, RJ Valentine… - … Syndrome and Obesity …, 2014 - ncbi.nlm.nih.gov
Abstract Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-
cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide …
cell dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide …
[PDF][PDF] AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan - 2014 - scienceopen.com
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
[PDF][PDF] AMPK activation: a therapeutic target for type 2 diabetes?
KA Coughlan - 2014 - Citeseer
Type 2 diabetes (T2D) is a metabolic disease characterized by insulin resistance, β-cell
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …
dysfunction, and elevated hepatic glucose output. Over 350 million people worldwide have …